1.Vieth M, Cummins DJ.. (2000) DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors., 43 (16):[PMID:10956210][10.1021/jm990609e]
2.Woodard CL, Li Z, Kathcart AK, Terrell J, Gerena L, Lopez-Sanchez M, Kyle DE, Bhattacharjee AK, Nichols DA, Ellis W, Prigge ST, Geyer JA, Waters NC.. (2003) Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases., 46 (18):[PMID:12930149][10.1021/jm0300983]
3.Li PK, Xiao Z, Hu Z, Pandit B, Sun Y, Sackett DL, Werbovetz K, Lewis A, Johnsamuel J.. (2005) Conformationally restricted analogs of Combretastatin A-4 derived from SU5416., 15 (24):[PMID:16213720][10.1016/j.bmcl.2005.09.001]
4.Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, Rosso E, Zambon A, Scapozza L, McDonald NQ, Lucchini V, Gambacorti-Passerini C.. (2010) Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors., 18 (4):[PMID:20117004][10.1016/j.bmc.2010.01.011]
5.Prado-Prado FJ, García-Mera X, González-Díaz H.. (2010) Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species., 18 (6):[PMID:20185316][10.1016/j.bmc.2010.01.068]
6.Babkov D, Bezsonova E, Sirotenko V, Othman E, Klochkov V, Sosonyuk S, Lozinskaya N, Spasov A.. (2023) 3-Arylidene-2-oxindoles as GSK3β inhibitors and anti-thrombotic agents., 87 [PMID:37054760][10.1016/j.bmcl.2023.129283]
